NBIX - Neurocrine Biosciences Inc logo

NBIX

Neurocrine Biosciences Inc

Neurocrine Biosciences develops and commercializes pharmaceuticals targeting neurological, psychiatric, endocrine, and immunological disorders. Key products include INGREZZA for tardive dyskinesia, Orilissa for endometriosis, and treatments for various movement disorders.

⚕️ Healthcare NASDAQ Listed 1996 $ USD
$1,000 invested 30 years ago$20,426today

Score Overview

1 Year
Score9.2
Net Growth47.41%
Net TrendGrew
Net Income Consistency
Rev Growth17.95%
Rev TrendGrew
Revenue Consistency
5 Years
Score9.5
Net Growth6x
Net TrendEvery year
Net Income Consistency
Rev Growth197.65%
Rev TrendEvery year
Revenue Consistency
10 Years
Score8.2
Net Growth6x
Net Trend80%
Net Income Consistency69%
Rev Growth223x
Rev TrendEvery year
Revenue Consistency90%
20 Years
Score6.4
Net Growth7x
Net Trend60%
Net Income Consistency40%
Rev Growth84x
Rev Trend70%
Revenue Consistency79%
30 Years
Score5.6
Net Growth118x
Net Trend50%
Net Income Consistency26%
Rev Growth174x
Rev Trend63%
Revenue Consistency46%
All Time
Score5.7
Net Growth118x
Net Trend50%
Net Income Consistency26%
Rev Growth174x
Rev Trend63%
Revenue Consistency45%

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-07
$ 163.41
1 Year2025-08-07
$ 125.6030.10%
5 Years2021-08-06
$ 89.5782.44%
10 Years2016-08-05
$ 49.97227.02%
20 Years2006-08-07
$ 8.7718x
30 Years1996-08-07
$ 8.0020x
All Time1996-05-23
$ 12.5013x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 3.37B$ 705M$ 389M
2025$ 2.86B$ 478M$ 1.48B
2024$ 2.35B$ 341M$ 1.07B
2023$ 1.88B$ 249M$ 1.03B
2022$ 1.48B$ 154M$ 989M
2021$ 1.13B$ 89M$ 711M
2020$ 1.04B$ 407M$ 801M
2019$ 788M$ 37M$ 670M
2018$ 451M$ 21M$ 650M
2017$ 161M-$ 142M$ 515M
2016$ 15M-$ 141M$ 307M
2015$ 19M-$ 88M$ 379M
2014$ 0.00-$ 60M$ 193M
2013$ 2M-$ 46M$ 145M
2012$ 53M$ 5M$ 173M
2011$ 77M$ 37M$ 129M
2010$ 33M-$ 7M$ 126M
2009$ 2M-$ 51M$ 53M
2008$ 3M-$ 88M$ 80M
2007$ 1M-$ 207M$ 179M
2006$ 39M-$ 107M$ 182M
2005$ 123M-$ 22M$ 273M
2004$ 85M-$ 45M$ 301M
2003$ 139M-$ 30M$ 453M
2002$ 18M-$ 94M$ 244M
2001$ 41M-$ 36M$ 319M
2000$ 14M-$ 28M$ 164M
1999$ 16M-$ 16M$ 91M
1998$ 16M-$ 20M$ 11M
1997$ 26M$ 5M$ 15M
IPO1996$ 19M$ 5M$ 11M